Pfizer Animal Health to Expand Access to E. coli O157 Vaccine from Epitopix for Beef Cattle
FOR IMMEDIATE RELEASE
|Elinore White||Jennifer Ryan|
|Pfizer Animal Health||Bader Rutter|
Salmonella Newport Cattle Vaccine Also Part of Pfizer Animal Health’s Licensing Agreement
NEW YORK, June 11, 2010 — Pfizer Animal Health today furthered its commitment to safe
food from cattle by announcing a global licensing agreement with Epitopix that will expand
access to its conditionally licensed Escherichia Coli Bacterial Extract vaccine* to U.S. cattle
producers this fall.
“Pfizer Animal Health supports cattle producers’ continuing strides against harmful
bacteria, often the most frequent causes of food borne illnesses in people,” said Juan Ramón
Alaix, president, Pfizer Animal Health. “We want more cattle producers to benefit from this
important vaccine to help reduce the prevalence and shedding of E. coli.”
The U.S. Department of Agriculture (USDA) granted a conditional license last year to
Epitopix for this first and only Escherichia Coli Bacterial Extract vaccine available in the U.S. It
is labeled for use in cattle to help reduce the prevalence of E. coli O157 in cattle and feces.
This helps to minimize E. coli exposure and infection of herd-mates.
As part of its licensing agreement, Pfizer Animal Health also acquired global rights to
Epitopix’ conditionally licensed Salmonella Newport bacterial extract vaccine*. Currently
available in the U.S. from Agri Laboratories, Ltd., of St. Joseph, Missouri under a USDA
conditional license, it will become an exclusive part of Pfizer Animal Health’s livestock portfolio
in the U.S. beginning in 2011
Pfizer Animal Health and Epitopix will conduct additional potency and efficacy studies
on both vaccines to secure a full license for each from the USDA. Terms of the global licensing
agreement were not disclosed.
“The R&D strength, global reach, and marketing expertise of Pfizer Animal Health make
it an ideal partner for Epitopix,” said Epitopix General Manager Jim Sandstrom. “By working in
close cooperation, our mutual aim is to quickly broaden the availability of these important
vaccines to the beef and dairy industries, as part of Pfizer Animal Health’s comprehensive
portfolio of cattle products and services.”
About E. coli Infection in People
The U.S. Centers for Disease Control (CDC) estimates approximately 70,000 cases
occur in people annually. However, the CDC acknowledges that most cases of E. coli O157 go
unreported. The symptoms of E. coli O157 infections vary for each person but often include
severe stomach cramps, diarrhea (often bloody), and vomiting. If there is fever, it usually is not
very high (less than 101˚F/less than 38.5˚C). Most people get better within 5–7 days. Some
infections are very mild, but others are severe or even life-threatening.
Epitopix LLC was founded in 2002 as an affiliate of Willmar Poultry Company, a
subsidiary of Life-Science Innovations headquartered in Willmar, Minn. at the MinnWest
Technology Campus, a 110 acre privately-owned technology business park. The mission of
Epitopix is to provide the food animal industry with novel bacterial vaccines with the potential to
be more broadly cross-protective and safer than conventional whole-cell bacterins or live
bacterial vaccines. Epitopix owns a family of patents related to the utilization of bacterial ironacquisition
proteins for use as vaccine antigens. For more information, visit www.Epitopix.com.
About Pfizer Animal Health
Pfizer, Inc, the world’s largest research-based biomedical and pharmaceutical company,
also is a world leader in discovering and developing innovative animal vaccines and
prescription medicines, investing an estimated $300 million annually. In the first quarter of
2010, Pfizer Animal Health generated revenue of $846 million, and for full-year 2009, $2.8
billion, including revenue from Wyeth/Fort Dodge since Pfizer’s acquisition in October.
In addition to helping assure a safe, global food supply from healthy food animals, Pfizer
Animal Health also helps dogs, cats and horses to live healthy longer. For additional
information on Pfizer’s portfolio of animal products and services, visit
*Notice: This product license is conditional. Efficacy and/or potency of this product have not
been fully demonstrated. Consultation with a veterinarian is recommended.
©2010 Pfizer Animal Health. All rights reserved. GCA10053.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States